What do DMEK and DSAEK stand for, and what is the difference in these two transplants?
DMEK stands for Descemet’s Membrane Endothelial Keratoplasty and DSAEK stands for Descemet’s Stripping Automated Endothelial Keratoplasty. The names can be confusing. Both surgeries involve first stripping out the patient’s (host’s) old Descemet’s membrane and corneal endothelium. The “automated” in DSAEK really just refers to the automated device that cuts the thickness of the donor cornea.
DMEK is more selective than DSAEK. Both DMEK and DSAEK remove Descemet’s membrane and endothelium. DMEK adds only a new Descemet’s membrane and endothelium. DSAEK also adds a new Descemet’s membrane and endothelium but with a layer of donor stroma. A way to remember this is to pretend that that the “S” in DSAEK stands for “stroma.” The difference between DMEK and DSAEK can be explained with a wall paper analogy. Let’s say your wall needs new wallpaper. In both DMEK and DSAEK, the old wall paper is removed. With DMEK, only new wallpaper is inserted. With DSAEK, a new piece of drywall that has new wallpaper on it is inserted on top of the old drywall.
With OCT scanning it is easy to see the DSAEK transplant because it has a layer of stroma with it (red arrows). The graft appears as a wedge of tissue on the inner layer of the host cornea.
DMEK is almost impossible to see unless it is not yet fully attached. This image of a partially separated DMEK (arrows) shows just how thin the graft is when no stroma is transplanted. This image also shows how important these grafts are to the cornea, because any area that doesn’t have the graft attached is more swollen.
What are DMEK and DSAEK used for?
DMEK and DSAEK are used to treat blurry vision due to disorders of a patient’s corneal endothelium (endothelial keratoplasties). They involve removing a patient’s diseased Descemet’s membrane with the endothelial cells that live on it, then transplanting a new Descemet’s membrane and endothelium.
If a patient has severe opacification or scarring of the corneal stroma, it may be necessary to transplant more of the cornea with a full-thickness Penetrating Keratoplasty (PK) transplantation. In the age of selective keratoplasty, PK is contraindicated for strictly endothelial disease unless there are extenuating circumstances that would prevent the success of DMEK or DSAEK.
The corneal endothelium can become sick and in need of replacement due to genetic disease (Fuchs endothelial dystrophy, posterior polymorphous corneal dystrophy, etc), inflammatory or autoimmune disease (iritis, endotheliitis, etc), trauma, or prior intraocular surgeries.
We all lose corneal endothelial cells throughout life. Since most of us are born with an excess of corneal cells, we typically don’t run out of them. If a person suffered an insult to their corneal endothelium at one point, gradual loss of endothelial cells can eventually lead to corneal swelling and poor vision. Thus, the symptoms often seem to develop gradually over time. Click here for the symptoms and mechanism of early corneal endothelial decompensation in Fuchs.
What is the difference in effect for DMEK & DSAEK?
DMEK provides better vision (average is 20/20 with some better and some worse), faster recovery (average is 2 to 4 weeks), and less rejection than any other type of corneal transplant (< 1% rejection in first 2 years). DMEK can also be combined with Toric IOLs so that cataract patients with corneal astigmatism can hope to be glasses free. Dr. Tenkman has several patients who required glasses preoperatively due to astigmatism who see 20/15 in each eye without glasses following DMEK.
The results of DSAEK are not as good when compared with DMEK. Average vision is about 20/30, recovery is 3 to 6 months, the rejection rate is 5 to 12% depending how thick the transplanted tissue is, and it cannot be used in conjunction with astigmatism correcting lenses in cataract surgery. Presumably, the vision is not as good because of the extra stromal tissue along with the interface between the host and donor stroma tissue. The increased rejection rate in DSAEK is also likely caused by the extra stromal tissue. White blood cells contained in the host stroma can freely travel into the donor stroma with no barrier blocking them. Once there, the white blood cells encounter the foreign tranplanted cells and can mount a rejection response. In contrast, all foreign cells in DMEK are hidden on the other side of the new Descemet’s membrane where the host’s white blood cells cannot find them. The recovery rate is slower in DSAEK because the transplant’s cut edge has no Descemet’s membrane on it. The bare exposed stroma is easily hydrated by the fluid in the eye creating corneal swelling. This swelling takes months to go away and does not resolve until new Descemet’s membrane grows onto this cut edge. With DMEK, by contrast, all the stroma is covered by Descemet’s membrane from day 1 so the corneal swelling goes away more quickly. Astigmatism is unpredictable with DSAEK since the thicker graft carries some unmeasurable amount of astigmatism with it. Thus, calculations for a proper astigmatism correcting lens cannot be made before cataract surgery.
Click here for an overview of the various types of corneal transplantation surgery.
How often does the air have to be reinjected in DSAEK & DMEK to help fully attach the donor?
In experienced hands, DSAEK air reinjections are only required 1% of the time. Partial separations of DSAEK donors almost always seal down fully on their own. In the past, DMEK required air reinjection 25 to 30% of the time. Eventually, DMEK surgeons realized what types of DMEK partial separations are likely to seal down on their own. This combined with using longer lasting air mixtures has allowed us to reduce the air reinjection rate down to about 1%.
Why don’t most corneal surgeons perform DMEK?
Most corneal surgeons perform DSAEK instead because they find it easier to do. There are some corneal surgeons who don’t even perform DSAEK and still offer the far more invasive penetrating keratoplasty (PK) for purely endothelial disease. The challenge with DMEK was to devise a technique to peel the Descemet’s membrane and endothelial cell layer from a donor without tearing it, then insert it into the patient’s eye, uncurl it (the tissue wants to curl up naturally), and attach it… all while minimizing any direct touching of the donor since any touch kills some cells. Many thought such techniques would never develop. Thankfully they have, so with proper training and in good hands DMEK provides patients a minimally invasive way to restore vision.
What has Dr. Tenkman done to advance DMEK surgery?
Dr. Tenkman has helped to pioneer several DMEK techniques, including those to advance DMEK donor prep. If a donor is lost during preparation, which is done before the patient’s surgery, the patient’s surgery would need to be postponed. When he started performing DMEK donor preps at Price Vision Group, the published donor loss rate during attempted DMEK preps was about 20%. Dr. Tenkman has pushed this donor loss rate far below 1%. Dr. Tenkman discovered donor horseshoe tears, “smile configuration,” and other challenges, and developed techniques to handle these DMEK donor prep difficulties. As a result, over his last 300 donor preps, Dr. Tenkman only found ONE cornea donor that wasn’t useable for DMEK. His techniques and results were published in the Cornea Journal (click here to view the paper). He also helped pioneer techniques to implant DMEK donors inside the patient’s eye. He discovered how to unlock point lock folds, how to gently flip a donor out of taco configuration by using gentle bursts of fluid, and has developed techniques to successfully perform DMEK in eyes that other DMEK surgeons would think challenging or not possible, including eyes with prior glaucoma surgery or tubes, eyes with prior anterior chamber intraocular lenses, eyes with previous PK transplants, and eyes with prior vitrectomy. To date, all eyes that Dr. Tenkman attempted DMEK on were successful. Less than 1% of the time, his initial DMEK surgery had to be repeated due to rejection or other problems, but all repeats to date have been successful.
Dr. Tenkman performed successful DMEK for his mom.
Should my surgeon ever choose DSAEK over a DMEK?
As mentioned above, most cornea surgeons do not perform DMEK. It requires more practice and experience. Dr. Tenkman may still select DSAEK for very specific cases, but he typically does DMEK for most patients.
Is DMEK guaranteed to make me 20/20?
No. The average patient sees some or all the letters on the 20/20 line. Some see better and some see worse. Even if the cornea is perfect, a person might not see 20/20 because of imperfections elsewhere in the eye. The same is true with “perfect” cataract surgery. Every eye has different potential. We will inform you of any other problems that may limit your final vision before surgery when possible.
Are steroid drops needed life-long after DMEK or DSAEK
Studies have proven that long-term rejection episodes are less likely if the patient at least maintains low potency steroid drops once a day. That being said, it would be safe to closely watch patients without steroid drops if they have trouble tolerating them. The rejection rate after stopping steroid drops long term for DMEK is about 6%.
Do I have to worry about my DMEK or DSAEK ever “falling off” the back of my cornea? How long will my transplant last
We watch you closely after surgery to ensure that the attachment process is successful, which can take a few weeks to complete. Once the donor becomes “one” with your cornea, it cannot fall off.
Traditional full thickness corneal transplants last about 20 years. Cell count studies show that transplants still gradually lose endothelial cells like any other healthy cornea, but usually at a faster rate. The transplant fails when the endothelial cell counts fall low enough. Since DMEK and DSAEK are relatively new, it is not possible to say how long they will last. Preliminary data is encouraging, however, especially for DMEK. There is variation between transplants, but early data suggest some transplants might last one’s lifetime. Either way, replacement is possible.
Dr. Tenkman is studying variables that may reveal which donors have cells that are more resistant to death and also surgical techniques that are minimally harmful to endothelial cells. Many surgeons suggest it is normal to lose 30 to 50% of the donor’s endothelial cells during surgery. We have some early data suggesting less than 10% cell loss from surgery when selecting a specific subset of donors.